At #AACR26: Results from CAR-PRISM Trial. Dr. Omar Nadeem says in a small trial for pts with high-risk smoldering myeloma, "This is the 1st time we've seen universal minimal residual disease negativity with a one-time treatment administration." @danafarber.bsky.social
➡️ bit.ly/4tmxcmW
